drugset / Trial / NCT06025409
Evaluate the Efficacy and Safety of DWJ108J
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-02-28
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 5.625 mg | Subcutaneous |
| Subject | Leuprolide | Other / unclassified | 11.25 mg | Subcutaneous |